Evidence map›Paper›PMID 35759152›Full record

Observational studyJournal of neuro-oncology2022

Accuracy and safety of 101 consecutives neurosurgical procedures for newly diagnosed central nervous system lymphomas: a single-institution experience.

Ilyes Aliouat, Alessandro Moiraghi, Giorgia Antonia Simboli, Rudy Birsen, Angela Elia, Alexandre Roux, Jérôme Tamburini, Edouard Dezamis, Eduardo Parraga, Chiara Benevello and 7 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Ilyes AliouatDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Alessandro MoiraghiDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Giorgia Antonia SimboliDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Rudy BirsenHematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Angela EliaDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Alexandre RouxDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Jérôme TamburiniHematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Edouard DezamisDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Eduardo ParragaDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Chiara BenevelloDepartment of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Diane DamottePathology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Corentin ProvostInstitute of Psychiatry and Neuroscience of Paris, IMABRAIN, INSERM U1266, Université de Paris, F-75014, Paris, France.
Catherine OppenheimInstitute of Psychiatry and Neuroscience of Paris, IMABRAIN, INSERM U1266, Université de Paris, F-75014, Paris, France.
Didier BouscaryHematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Fabrice ChretienDepartment of Neuropathology, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 75014, Paris, France.
Marc Zanello *Department of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France.
Johan Pallud *Department of Neurosurgery, GHU-Paris Psychiatrie et Neurosciences, Hôpital Sainte Anne, 1 rue Cabanis, 75014, Paris Cedex 14, France. johanpallud@hotmail.com.
Institut de Psychiatrie et Neurosciences de Paris · FRCentre Hospitalier Sainte-Anne · FRHôpital Cochin · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRFHU Neurovasc · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBrain surgery is required to ascertain the diagnosis of central nervous system lymphoma. We assessed the diagnostic yield and safety of the surgical procedures, the predictors of postoperative morbidity, and of overall survival.

methodsObservational single-institution retrospective cohort study (1992-2020) of 101 consecutive adult patients who underwent stereotactic biopsy, open biopsy, or resection for a newly diagnosed central nervous system lymphoma.

resultsThe diagnostic yield was 100% despite preoperative steroid administration in 48/101 cases (47.5%). A preoperative Karnofsky Performance Status score less than 70 (p = 0.006) was an independent predictor of a new postoperative focal neurological deficit (7/101 cases, 6.9%). A previous history of hematological malignancy (p = 0.049), age 65 years or more (p = 0.031), and new postoperative neurological deficit (p < 0.001) were independent predictors of a Karnofsky Performance Status score decrease 20 points or more postoperatively (13/101 cases, 12.9%). A previous history of hematological malignancy (p = 0.034), and preoperative Karnofsky Performance Status score less than 70 (p = 0.024) were independent predictors of postoperative hemorrhage (13/101 cases, 12.9%). A preoperative Karnofsky Performance Status score less than 70 (p = 0.019), and a previous history of hematological malignancy (p = 0.014) were independent predictors of death during hospital stay (8/101 cases, 7.9%). In the 82 immunocompetent patients harboring a primary central nervous system lymphoma, age 65 years or more (p = 0.044), and time to hematological treatment more than 21 days (p = 0.008), were independent predictors of a shorter overall survival. A dedicated hematological treatment (p < 0.001) was an independent predictor of a longer overall survival.

conclusionBrain biopsy is feasible with low morbidity for central nervous system lymphomas. Postoperatively, patients should be promptly referred for hematological treatment initiation.

Indexed as

Brain NeoplasmsHematologic NeoplasmsLymphomaAdultAgedCentral Nervous SystemHumansNeurosurgical ProceduresRetrospective StudiesTreatment OutcomeBiopsyEfficacyLymphomaSafetySteroidSurgery

Identifiers

PMID35759152
OpenAlexW4283662165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.